Understanding Immunity Persistence After Adolescent MenC Vaccination

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

134 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to evaluate the duration of immunity after a booster dose of a MenC-CRM vaccine given to adolescents between 13 and 15 years of age. Does seroprotection persist beyond teenage years and into the early twenties? This is the age group which is most likely to carry the organism and to transmit it to other members of the population. If a booster dose of MenC vaccine given to adolescents does produce protective levels of antibody which persist into early adulthood, this would strengthen the case for such a booster to be added to the UK routine immunisation schedule, to reduce the risk of a resurgence of the disease in the future.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Understanding the Persistence of Immunity After MenC Vaccines

NCT01126996

Healthy

COMPLETED

Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine

NCT00856297

Meningococcal Meningitis

COMPLETED PHASE3

Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612

NCT00390143

Infections, Meningococcal

COMPLETED PHASE2

Can we Reduce the Number of Vaccine Injections for Children?

NCT01129518

Invasive Meningococcal Disease

COMPLETED PHASE4

Persistence of Immune Response After Vaccination With MCC

NCT00310687

Prevention of Meningococcal Infection

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Antibody Persistance After Booster Dose of Men C Vaccine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Follow-on blood sample from previous study

Venepuncture and blood sample collection.

Intervention Type OTHER

Venepuncture and blood sample collection.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Venepuncture and blood sample collection.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants who completed clinical study M14P2E1
* Participant who are willing to participate and who would be expected to comply with the requirements of the protocol
* Participants who have given informed consent for participation in the study

Exclusion Criteria

* History of invasive meningococcal C disease (or any case of invasive meningococcal disease where the serotype was unknown)
* Confirmed or suspected immunosuppressive or immunodeficient conditions, including human immunodeficiency virus (HIV) infection
* Severe blood clotting disorders

Minimum Eligible Age

20 Years

Maximum Eligible Age

23 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes